Quantbot Technologies LP Takes Position in Boston Scientific Corporation $BSX

Quantbot Technologies LP acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 235,949 shares of the medical equipment provider’s stock, valued at approximately $10,070,000. Boston Scientific makes up approximately 0.4% of Quantbot Technologies LP’s portfolio, making the stock its 28th largest holding.

A number of other hedge funds also recently bought and sold shares of BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Sfam LLC purchased a new position in Boston Scientific during the fourth quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. purchased a new position in Boston Scientific during the fourth quarter worth approximately $33,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of several analyst reports. Canaccord Genuity Group dropped their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a report on Wednesday, July 29th. Barclays lowered their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Weiss Ratings lowered shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Finally, Raymond James Financial restated an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Price Performance

BSX stock opened at $50.39 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56. The business has a fifty day moving average of $46.34 and a two-hundred day moving average of $57.86.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.